Differential efficacy of clarithromycin in lung versus thigh infection models

被引：18

作者：

Maglio, D

Capitano, B

Banevicius, MA

Geng, QM

Nightingale, CH

Nicolau, DP

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06102 USA

[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06102 USA

[3] Hartford Hosp, Res Off, Hartford, CT 06102 USA

来源：

CHEMOTHERAPY | 2004年 / 50卷 / 02期

关键词：

pneumonia model; thigh infection model; clarithromycin; Streptococcus pneumoniae;

D O I：

10.1159/000077804

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Differences in clarithromycin disposition and the resulting changes in bacterial density were studied using mouse lung and thigh infection models. Methods: Clarithromycin activity was evaluated against seven Streptococcus pneumoniae isolates with efflux-mediated resistance in both murine lung and thigh infection models. Intrapulmonary disposition of clarithromycin was also studied. Results: Consistent bacterial kill was observed in the lung model, whereas no drug effect was observed in the thigh model. Conclusion: These differences in bacterial density were supported by high concentrations observed in epithelial lining fluid as compared to serum. Copyright (C) 2004 S. Karger AG, Basel.

引用

收藏

页码：63 / 66

页数：4

相关论文

共 11 条

[1] The in vivo-in vitro paradox in pneumococcal respiratory tract infections [J].

Bishai, W .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) :433-436

[2] INTRAPULMONARY PHARMACOKINETICS OF CLARITHROMYCIN AND OF ERYTHROMYCIN [J].

CONTE, JE ;

GOLDEN, JA ;

DUNCAN, S ;

MCKENNA, E ;

ZURLINDEN, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :334-338

[3] Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae [J].

Mattoes, HM ;

Banevicius, M ;

Li, DD ;

Turley, C ;

Xuan, DW ;

Nightingale, CH ;

Nicolau, DP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2092-2097

[4] Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections [J].

Nicolau, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :61-70

[5]

Nicolau DP, 2000, AM J MANAG CARE, V6, pS1202

[6] Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model [J].

Nicolau, DP ;

Banevicius, MA ;

Nightingale, CH ;

Quintiliani, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (12) :3033-3035

[7] In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae [J].

Okamoto, H ;

Miyazaki, S ;

Tateda, K ;

Ishii, Y ;

Yamaguchi, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3250-3252

[8] Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin [J].

Patel, KB ;

Xuan, DW ;

Tessier, PR ;

Russomanno, JH ;

Quintiliani, R ;

Nightingale, CH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2375-2379

[9] Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers [J].

Rodvold, KA ;

Gotfried, MH ;

Danziger, LH ;

Servi, RJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1399-1402

[10] ANTIBIOTIC ASSAYS IN MUSCLE - ARE CONVENTIONAL TISSUE-LEVELS MISLEADING AS INDICATOR OF THE ANTI-BACTERIAL ACTIVITY [J].

RYAN, DM ;

CARS, O .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1980, 12 (04) :307-309